Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
16.60
0.00 (0.00%)
Aug 19, 2026, 1:36 PM CST
Anxo Pharmaceutical Revenue
Anxo Pharmaceutical had revenue of 440.48M TWD in the half year ending December 31, 2025, a decrease of -10.97%. This brings the company's revenue in the last twelve months to 878.88M, down -0.49% year-over-year. In the year 2025, Anxo Pharmaceutical had annual revenue of 843.26M, down -5.81%.
Revenue (ttm)
878.88M
Revenue Growth
-0.49%
P/S Ratio
1.06
Revenue / Employee
n/a
Employees
307
Market Cap
927.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 843.26M | -52.06M | -5.81% |
| Dec 31, 2024 | 895.32M | -44.62M | -4.75% |
| Dec 31, 2023 | 939.94M | 73.67M | 8.50% |
| Dec 31, 2022 | 866.27M | 42.17M | 5.12% |
| Dec 31, 2021 | 824.10M | -42.01M | -4.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.40B |
| Prince Pharmaceutical | 1.06B |
| Excelsior Biopharma | 936.92M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Winston Medical Supply | 632.80M |
| Bioray Biotech | 222.73M |
| General Biologicals | 215.74M |